#信小呆不想再被打扰#
靠谱不？
Semaglutide, an injectable drug made by the pharmaceutical company Novo Nordisk, was approved Friday by the Food and Drug Administration, for patients struggling with chronic obesity.
"We don't use those terms lightly," Northwestern University Feinberg School of Medicine professor Dr. Robert F. Kushner, an obesity medicine specialist and trial investigator for the drug, told ABC News. "I've been involved in the field for 40 years. The reason we think that way, it results in amount of weight loss of an average of 15% or more, which we have not seen before."

#国药新冠疫苗为何能获世卫紧急使用认证#
国药疫苗在不同国家的使用效果尚有争议。
A peer-reviewed study published May 26 found the Sinopharm vaccine was 78 percent effective against symptomatic illness, but the trial participants were mostly healthy young men, the Journal reports. "In a separate, unpublished, real-world study of Sinopharm in Serbia, 29 percent of 150 participants were found to have zero antibodies against the virus three months after they received the first of two shots of the vaccine. The average age of the people who participated in the Serbian study was higher than 65."

【国药董事长：下半年国药新冠疫苗全球供应可超10亿剂】6月2日晚，在青岛举行的博鳌亚洲论坛全球健康论坛第二届大会“实现全民健康—新冠疫苗的研发、可及性与可负担性”分论坛上，中国医药集团有限公司党委书记、董事长刘敬桢表示，在保证国内需求前提下，国药集团有能力在今年下半年向中国其它国家提供超过10亿剂的新冠疫苗。目前中国正在使用国药集团的两种疫苗，其中一种已获得世界卫生组织的紧急使用批准，这是疫苗被纳入COVAX计划的前提条件。据悉，国药集团还计划为正在进行早期临床试验的第三种疫苗建立一条生产线。China National Pharmaceutical Group (Sinopharm) has the capacity to provide more than 1 billion COVID-19 vaccine doses to the world beyond China in the second half of this year, Sinopharm chairman Liu Jingzhen said late Wednesday. Two vaccines from Sinopharm are being used in China, one of which has gained emergency use approval from the World Health Organization, a prerequisite for a vaccine to be included in the COVAX initiative. Besides, Sinopharm has also planned a manufacturing facility for a third shot, which is being tested in an early-stage clinical trial, Liu added.